FLOW trial semaglutide kidney claims: what the data actually says

What did @weightdoc actually say?

The creator summarized the FLOW trial, a large randomized study of semaglutide in people with type 2 diabetes and chronic kidney disease. They cited a 24% reduction in major kidney disease events, 18% fewer major adverse cardiac events, and 20% lower all-cause mortality. They also raised the mechanism question directly, noting the authors pointed to GLP-1 receptors on kidney tissue as a possible explanation beyond weight loss alone.

This is a content creator engaging seriously with a primary source published in the New England Journal of Medicine. That is not nothing. Most TikTok health content does not get this granular with trial data. The framing was responsible, the numbers were close to accurate, and they flagged uncertainty around mechanism rather than overstating certainty. Credit where it is due.

Does the science back this up?

Yes, with some precision issues worth noting. The FLOW trial (Perkovic et al., 2024, NEJM) enrolled 3,533 participants, not just "over 3,000," across 28 countries. Participants had type 2 diabetes and chronic kidney disease and were randomized to semaglutide 1 mg weekly or placebo.

The primary endpoint, a composite of kidney failure, at least 50% decline in eGFR, kidney-related death, or cardiovascular death, was reduced by 24% in the semaglutide group (hazard ratio 0.76, 95% CI 0.66-0.88). The trial was stopped early by the independent data monitoring committee in late 2023, not by the sponsor, because the prespecified efficacy boundary was crossed. The creator's characterization of the results being "so good" that the trial was stopped is accurate in spirit, though the language is informal.

The cardiovascular benefit the creator described as 18% is directionally correct. The 20% all-cause mortality reduction is also consistent with reported findings. These are meaningful effect sizes, not marginal signals.

What did they get wrong (or right)?

The mechanism discussion is where things get more complicated, and the creator deserves partial credit for acknowledging complexity rather than flattening it.

They said the authors noted that "the effects of Samaaglitide on the kidneys were unrelated to changes in body size." This is a reasonable interpretation of the paper's exploratory analyses, which found kidney benefits persisted after adjusting for weight change. But calling it definitively "unrelated" is slightly stronger than what the data support. Mediation analyses in trials like FLOW can only go so far. The authors themselves used cautious language about plausible direct renal effects.

The claim about GLP-1 receptors on kidney tissue is biologically plausible and consistent with preclinical data, but the clinical significance of those receptors in humans is still being worked out. Researchers including Rajasekeran et al. (2017, Diabetologia) have documented GLP-1 receptor expression in renal proximal tubules, and there is evidence of direct anti-inflammatory effects. The creator was right to mention it, but presenting it as a settled explanation overstates where the science currently sits.

One thing the creator did not mention: most FLOW participants were already on renin-angiotensin system inhibitors, the current standard of care for diabetic kidney disease. The benefit was seen on top of that background therapy. That context matters for anyone trying to understand real-world applicability.

What should you actually know?

If you have type 2 diabetes and chronic kidney disease, this trial is genuinely significant. Before FLOW, the evidence base for kidney-protective therapies had expanded with SGLT2 inhibitors (Heerspink et al., 2020, NEJM, DAPA-CKD trial). FLOW adds semaglutide to that picture and suggests these drug classes may have complementary mechanisms.

What this does not mean: semaglutide is not a cure for kidney disease. The trial studied a specific population, people with type 2 diabetes and CKD stages 2-4, using a specific dose administered weekly. Results from a trial population do not automatically translate to every person with kidney problems. Anyone with CKD considering semaglutide should be having that conversation with their nephrologist or endocrinologist, not making decisions based on a TikTok video, including this one.

The early termination of FLOW is worth understanding. Trials stopped early for efficacy can sometimes overestimate effect sizes (Montori et al., 2005, JAMA). That does not mean the results are wrong, but it is a reason to watch for longer-term follow-up data rather than treating the hazard ratios as final answers.

Bottom line on this video

This is one of the more accurate GLP-1 TikToks circulating right now. The creator read the primary source, cited real numbers, acknowledged mechanistic uncertainty, and did not make speculative leaps about who should be taking semaglutide. The informal pronunciation of "semaglutide" throughout is a minor distraction. The substance holds up well against the published trial. That said, a 3-minute video cannot capture the nuance of a trial this complex, and patients should not treat this summary as clinical guidance.